| Literature DB >> 28448534 |
Colleen Marie Bartman1,2, Yoshimasa Oyama1,3, Kelley Brodsky1,4, Ludmila Khailova1, Lori Walker4, Michael Koeppen5, Tobias Eckle1,2,4.
Abstract
A wide search for ischemic preconditioning (IPC) mechanisms of cardioprotection identified the light elicited circadian rhythm protein Period 2 (Per2) to be cardioprotective. Studies on cardiac metabolism found a key role for light elicited Per2 in mediating metabolic dependence on carbohydrate metabolism. To profile Per2 mediated pathways following IPC of the mouse heart, we performed a genome array and identified 352 abundantly expressed and well-characterized Per2 dependent micro RNAs. One prominent result of our in silico analysis for cardiac Per2 dependent micro RNAs revealed a selective role for miR-21 in the regulation of hypoxia and metabolic pathways. Based on this Per2 dependency, we subsequently found a diurnal expression pattern for miR-21 with higher miR-21 expression levels at Zeitgeber time (ZT) 15 compared to ZT3. Gain or loss of function studies for miR-21 using miRNA mimics or miRNA inhibitors and a Seahorse Bioanalyzer uncovered a critical role of miR-21 for cellular glycolysis, glycolytic capacity, and glycolytic reserve. Exposing mice to intense light, a strategy to induce Per2, led to a robust induction of cardiac miR-21 tissue levels and decreased infarct sizes, which was abolished in miR-21-/- mice. Similarly, first translational studies in humans using intense blue light exposure for 5 days in healthy volunteers resulted in increased plasma miR-21 levels which was associated with increased phosphofructokinase activity, the rate-limiting enzyme in glycolysis. Together, we identified miR-21 as cardioprotective downstream target of Per2 and suggest intense light therapy as a potential strategy to enhance miR-21 activity and subsequent carbohydrate metabolism in humans.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28448534 PMCID: PMC5407766 DOI: 10.1371/journal.pone.0176243
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Per2 dependent micro RNAs during cardiac ischemic preconditioning (IPC).
Shown are the 65 differentially regulated and Per2 dependent micro RNAs identified after IPC treatment of wildtype and Per2 mice.
| IP regulated | FC | FC | function | publication | species |
|---|---|---|---|---|---|
| mmu-miR-16 | 4.0278 | -1.2311 | prevents cardiac hypertrophy | J Cell Mol Med. 2015 Mar;19(3):608–19 | R |
| mmu-miR-409-5p | 6.9644 | 1.9053 | |||
| mmu-miR-154 | 5.6962 | 1.4241 | protect against cardiac dysfunction | Sci Rep. 2016 Mar 1;6:22442 | M |
| mmu-miR-326 | 5.6569 | 1.9053 | |||
| mmu-miR-24 | 5.579 | 1.7291 | inhibits cardiomyocyte apoptosis | J Cell Mol Med. 2015 Jan;19(1):103–12 | M |
| mmu-miR-27b | 5.2054 | 1.6702 | increases angiogenesis heart | Vase Cell. 2015 Jun 24;7:6 | M |
| mmu-miR-146a | 5.1337 | 1.9725 | inhibits cardiomyocyte apoptosis | Mol Ther Nucleic Acids. 2016 Mar 15;5:e296 | M |
| mmu-miR-126-3p | 4.7568 | -1.1329 | |||
| mmu-miR-25 | 4.6268 | 1.2397 | protects cardiomyocytes | lntJ Mol Sc i. 2015 Mar 10;16(3):5420–33. | R |
| mmu-miR-23b | 4.4383 | 1.7654 | upregulated in heart failure | Eur J Heart Fail. 2016 Apr 12. | H |
| mmu-miR-186 | 4.4383 | -1.021 | diagnosis of unstable angina pectoris | Eur Heart J. 2014 Aug 14;35(31):2106–14 | H |
| mmu-miR-191 | 4.4076 | 1.3195 | biomarkers for Ml | Biomed Res Int. 2014;2014:418628 | H |
| mmu-miR-150 | 4.2871 | 1.3195 | protect against cardiac fibrosis | Cell Physiol Biochem. 2016 May 17;38(6):2103–2122 | M |
| mmu-miR-342-3p | 4.2281 | 1.4948 | biomarker heart failure | Eur J Heart Fail. 2013 Oct;15(10):1138–47 | H |
| mmu-miR-28 | 4.1411 | 1.0867 | Eur Rev Med Pharmacal Sci. 2015; 19 (5) | M | |
| mmu-miR-99a | 4.1411 | 1.1487 | prevents cardiac hypertrophy | PloS One. 2016 Feb 25;11(2):e0148480 | M |
| mmu-miR-322 | 4.1125 | -1.0867 | protects against cardiac dysfunction | Biochim Biophys Acta. 2016 Apr;1862(4):611–21 | M |
| mmu-miR-30a | 4.084 | 1.7053 | protect against cardiac dysfurnction | Mol Cell Biochem. 2013 Jul;379(1–2):1–6 | M |
| mmu-miR-23a | 4.084 | 1.9185 | J Bioi Chem. 2012 Jan 2;287(1):589–99 | M | |
| mmu-miR-181b | 4.0278 | 1.9053 | upregulated in heart failure | Eur J Heart Fail. 2016 Apr 12. doi | H |
| mmu-miR-101a | 3.9724 | 1.1567 | protects cardiac fibroblasts | lntJ Biochem Cell Bioi. 2015 Aug;65: 155–64 | R |
| mmu-miR-505 | 3.9313 | 1.1368 | regenerative neonatal mouse heart | Cell Biochem Biophys. 2014 Sep;70(1):635–42 | M |
| mmu-miR-20a | 3.9177 | -1.3755 | prevents cardiac hypertrophy | PloS One. 2013 Nov13;8(11):e79133 | R |
| mmu-miR-199b | 3.8637 | -1.3755 | Cardiovasc Res. 2016 May 15;110(2):258–67 | M | |
| mmu-miR-324-5p | 3.8106 | 1.5157 | attenuates cardiomyocyte apoptosis | Cell Death Dis. 2015 Dec 3;6:e2007 | M |
| mmu-miR-30c | 3.7842 | 1.6818 | prevents cardiac hypertrophy | Circ Res. 2009 Jan 30;104(2):170–8 | M |
| mmu-miR-208b | 3.7064 | -2.4116 | biomarkers for LV remodling | lntJ Mol Sc i. 2014 Apr 4;15(4):5774–88. doi | H |
| mmu-miR-301a | 3.6808 | -1.5583 | |||
| mmu-let-7d | 3.6301 | 1.3287 | |||
| mmu-miR-582-5p | 3.6175 | -4.4229 | |||
| mmu-miR-466d-3p | 3.5554 | -1.1173 | |||
| mmu-miR-155 | 3.5308 | -1.0425 | J Am Heart Assoc. 2016 Apr 22;5(4) | M | |
| mmu-miR-532-3p | 3.4224 | 1.9931 | Cell Death Dis. 2015 Mar 12;6:e1677 | M | |
| mmu-miR-30e | 3.4105 | -1.0644 | |||
| mmu-miR-126-5p | 3.3636 | -1.0425 | |||
| mmu-miR-350 | 3.3636 | 1.1647 | Biochim Biophys Acta. 2013 Jan;1832(1) | R | |
| mmu-miR-148b | 3.3404 | 1.3566 | |||
| mmu-miR-541 | 3.3173 | 1.3947 | prevents cardiac hypertrophy | Cell Death Dis. 2014 Apr 10;5:e1171 | M |
| mmu-miR-301b | 3.3173 | -1.1647 | |||
| mmu-miR-181d | 3.2944 | 1.0425 | |||
| mmu-miR-106b | 3.2266 | -1.2924 | |||
| mmu-miR-151-5p | 3.2266 | 1.0353 | prevents arrythm ias in Ml | Pl oS One. 2013 Sep 9;8(9):e72985 | R |
| mmu-miR-128a | 3.2043 | 1.6133 | |||
| mmu-miR-425 | 3.1821 | 1.4044 | regu lates ANP product ion | Mol Cell Bioi. 2016 May 16. pii: MCB.01114-15 | H |
| mmu-miR-152 | 3.1821 | 1 | |||
| mmu-miR-99b | 3.1383 | 1.7901 | |||
| mmu-miR-22 | 3.1167 | 1.4845 | Cardioprotective | Gene. 2016 Mar 15;579(1):17–22 | R |
| mmu-miR-467c | 3.1167 | -1.2924 | |||
| Cardiovasc Res. 2010 Aug 1;87(3):431–9 | M | ||||
| mmu-miR-872 | 3.0738 | -1.0867 | |||
| mmu-let-7i | 3.0738 | 1.021 | |||
| mmu-miR-18a | 3.0738 | -1.5692 | |||
| mmu-let-7c | 3.0525 | 1.4743 | |||
| mmu-miR-17 | 3.0525 | -1.257 | |||
| mmu-let-7f | 3.0314 | -1.366 | |||
| mmu-miR-467e | 3.0105 | -1.6818 | |||
| mmu-miR-219 | 2.2974 | -4.1411 | |||
| mmu-miR-675-5p | 1.9521 | 3.1932 | |||
| mmu-miR-302c | 1.7654 | 24.4201 | |||
| mmu-miR-742 | 1.0281 | 3.9449 | |||
| mmu-miR-216a | -1.057 | 4.4076 | |||
| mmu-miR-343 | -3.1711 | -1.244 | |||
| mmu-miR-744 | -3.3636 | -1.014 | |||
| mmu-miR-679 | -3.4943 | -1.4191 | |||
| mmu-miR-292-3p | -5.8159 | -1.4743 |
IP = Ischemic Preconditioning, FC = Fold Change.